{"preliminary_commentary":{"by_channel":{"x_thread":87,"youtube":84,"podcast":52,"x_video":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05113251\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"DESTINY-Breast11","nct_id":"NCT05113251","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-breast11-nct05113251. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Trastuzumab deruxtecan","label":"Arm A","type":"EXPERIMENTAL"},{"description":"T-DXd, followed by THP","label":"Arm B","type":"EXPERIMENTAL"},{"description":"doxorubicin and cyclophosphamide, followed by THP","label":"Arm C","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-04-30","type":"ESTIMATED"},"conditions":["Breast Neoplasms","Breast Cancer","HER2-positive Early Breast Cancer"],"enrollment":{"count":927,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab Deruxtecan","otherNames":["T-DXd","Enhertu"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol","Onxol"],"type":"DRUG"},{"name":"Trastuzumab","otherNames":["Herceptin","Herzuma"],"type":"DRUG"},{"name":"Pertuzumab","otherNames":["Perjeta"],"type":"DRUG"},{"name":"Doxorubicin","otherNames":["Adriamycin","Rubex"],"type":"DRUG"},{"name":"cyclophosphamide","otherNames":["Neosar","Cytoxan"],"type":"DRUG"}],"last_update":"2026-08-11","lead_sponsor":"AstraZeneca","official_title":"A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-03-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Rate of Pathologic Complete Response (pCR).","timeFrame":"Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)"}],"references":[],"start_date":{"date":"2021-10-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05113251"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-breast11-nct05113251"}